NEW YORK, Feb. 21, 2018 -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Obalon Therapeutics, Inc. ("Obalon" or the "Company") (NASDAQ:OBLN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Obalon securities between October 5, 2016 and January 23, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/obln.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
On January 23, 2018, Obalon announced that it would cancel its previously announced public offering of Obalon common stock after its independent auditor, KPMG LLP, received a complaint from a “purported whistleblower” alleging “improper revenue recognition during the Company's fourth fiscal quarter of 2017.” On this news, Obalon’s share price fell $1.73, or 33.33%, to close at $3.46 on January 23, 2018.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) that the Company recognized revenue in violation of Generally Accepted Accounting principles (“GAAP”); (2) that the Company lacked adequate internal controls over accounting and financial reporting; and (3) that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Obalon’s business, operations, and prospects, were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/obln or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Obalon you have until April 16, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Samsung Electronics Shares Jump on HBM4 Mass Production Report
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 



